Page 1

Clinical Measures with Yes/No Values

Client: ABC Corporation

Study Population: 1,404

Total Population: 1520

Time Window of Baseline: 12/26/08 to 08/13/09

Time Window of Follow-Up: 10/16/09 to 11/14/09

Date of Comparison Report: 11/20/09

Version of Report: V9.3

Know Your Number® Aggregate Report

Comparisons Between Baseline & Follow-Up

Page 2Client: ABC Corporation

Date of Comparison Report: 11/20/09

Gender Distribution

Gender Number %

Male 1019 72.6

Female 385 27.4

Total 1404 100.0

Age Distribution

Age (years) Number %

21-30 207 14.7

31-40 432 30.8

41-50 410 29.2

51-60 293 20.9

61-70 61 4.3

71-80 1 0.1

>80 0 0.0

Total 1404 100.0

Ethnicity Distribution

Race Number %

White 1277 91.0

Black 21 1.5

Asian 9 0.6

Hispanic 66 4.7

Others 31 2.2

Total 1404 100.0

Study Population Demographics*

72.6%

27.4%

Male

Female

0

5

10

15

20

25

30

35

21-30 31-40 41-50 51-60 61-70 71-80 >80

Pe

rce

ntile

Age (years)

White

Black

Asian

Hispanic

Others

Page 3Client: ABC Corporation

Date of Comparison Report: 11/20/09

Baseline

(%)

Follow-Up

(%)

Difference*

(%)

Change**

(%)P Value***

Clinical Measures with Yes/No Values

Current smoking 34.8 33.5 -1.3 -3.7 0.0468

Overweight (BMI 25.0-29.9 kg/m2) 32.0 31.8 -0.2 -0.7 0.8291

Obesity (BMI>=30 kg/m2) 44.3 41.7 -2.6 -5.8 0.0008

High waist (male>40 inch, female>35 inch) 45.7 39.3 -6.3 -13.9 0.0000

Prehypertension (>=120/80 and <140/90 mmHg) 58.5 43.6 -14.9 -25.5 0.0000

Hypertension (>=140/90 mmHg) 11.7 13.0 1.3 11.0 0.2334

Metabolic syndrome**** 31.3 24.0 -7.3 -23.4 0.0000

Total cholesterol (>=200 mg/dL) 48.6 38.4 -10.3 -21.1 0.0000

HDL (<40 mg/dL) 27.8 23.1 -4.8 -17.1 0.0000

LDL>=130 mg/dL 39.1 30.8 -8.3 -21.1 0.0000

LDL>=ATP III suggested goal 31.2 26.7 -4.5 -14.4 0.0000

Triglyceride>=150 mg/dL 36.5 28.8 -7.6 -20.9 0.0000

Undiagnosed diabetes (glucose>=126 mg/dL) 4.7 3.6 -1.1 -22.7 0.0628

Prediabetes (100<=glucose<126 mg/dL) 23.5 26.0 2.5 10.6 0.0565

Clinical Measures with Numerical Values

Weight (lbs) 196.6 193.8 -2.8 -1.4 0.0000

BMI (kg/m2) 29.8 29.4 -0.5 -1.5 0.0000

Waist (inch) 38.8 38.1 -0.7 -1.9 0.0000

Exercise level (1=Low; 2=Moderate; 3=High) 1.7 1.8 0.1 7.6 0.0000

Systolic blood pressure (mmHg) 123.4 121.5 -1.9 -1.5 0.0000

Diastolic blood pressure (mmHg) 76.4 76.2 -0.2 -0.3 0.4129

Total cholesterol (mg/dL) 200.9 192.0 -8.9 -4.4 0.0000

HDL cholesterol (mg/dL) 47.9 49.1 1.3 2.7 0.0000

LDL cholesterol (mg/dL) 123.6 115.9 -7.6 -6.2 0.0000

Triglyceride (mg/dL) 151.6 136.7 -14.8 -9.8 0.0000

Fasting glucose (mg/dL) 100.7 100.1 -0.6 -0.6 0.2813

* Difference (%) = Follow-up (%) minus Baseline (%)

** Change (%) = Difference (%) divided by Baseline (%)

**** Metabolic syndrome is diagnosed based on the ATP III guideline criteria.

*** P value is based on a paired t-test or chi-square analysis. P<0.05 indicates that the difference between the baseline and

follow-up evaluations is statistically significant and is shown in red.

Health Status and Risk Factor Profile:

Changes Between Baseline and Follow-Up Evaluations

Page 4ABC Corporation

11/20/09

Baseline

(%)

Follow-Up

(%)

Difference*

(%)

Change**

(%)P Value***

Clinical Measures with Yes/No Values

Current smoker 41.4 39.8 -1.6 -3.8 0.2574

Overweight (BMI 25.0-29.9 kg/m2) 29.8 28.3 -1.6 -5.3 0.3968

Obese (BMI>=30 kg/m2) 39.3 38.2 -1.0 -2.7 0.4504

High waist measurement (female>35 inches) 50.5 44.5 -6.0 -11.9 0.0012

Prehypertension (>=120/80 and <140/90 mmHg) 43.2 32.2 -11.0 -25.5 0.0003

Hypertension (>=140/90 mmHg) 7.6 7.3 -0.3 -3.4 0.8761

Metabolic syndrome**** 25.4 17.3 -8.1 -32.0 0.0003

Total cholesterol >=200 mg/dL 50.0 40.3 -9.7 -19.4 0.0000

HDL <40 mg/dL 11.3 9.9 -1.3 -11.6 0.3987

LDL >=130 mg/dL 38.0 28.8 -9.2 -24.1 0.0000

LDL >=ATP III suggested goal 24.3 19.1 -5.2 -21.5 0.0080

Triglyceride >=150 mg/dL 27.0 18.1 -8.9 -33.0 0.0000

Undiagnosed diabetes (glucose>=126 mg/dL) 3.4 2.4 -1.0 -30.8 0.2487

Prediabetes (100<=glucose<126 mg/dL) 16.2 18.8 2.6 16.1 0.2456

Clinical Measures with Numerical Values

Weight (lbs) 169.3 167.3 -2.0 -1.2 0.0006

BMI (kg/m2) 29.1 28.7 -0.3 -1.1 0.0027

Waist (inch) 36.1 35.3 -0.8 -2.2 0.0000

Exercise level (1=Low; 2=Moderate; 3=High) 1.7 1.7 0.1 3.5 0.1400

Systolic blood pressure (mmHg) 118.2 116.5 -1.7 -1.5 0.0059

Diastolic blood pressure (mmHg) 73.6 72.9 -0.7 -0.9 0.1809

Total cholesterol (mg/dL) 201.7 194.2 -7.6 -3.7 0.0000

HDL cholesterol (mg/dL) 55.1 56.3 1.3 2.3 0.0018

LDL cholesterol (mg/dL) 122.2 115.4 -6.8 -5.6 0.0000

Triglyceride (mg/dL) 122.3 112.7 -9.6 -7.8 0.0011

Fasting glucose (mg/dL) 96.9 96.1 -0.8 -0.8 0.3578

Client:

Date of Comparison Report:

Health Status and Risk Factor Profile:

Changes Between Baseline & Follow-Up (continued)

Females

Page 5Client: ABC Corporation

Date of Comparison Report: 11/20/09

Baseline

(%)

Follow-Up

(%)

Difference*

(%)

Change**

(%)P Value***

Clinical Measures with Yes/No Values

Current smoker 32.4 31.3 -1.1 -3.4 0.1309

Overweight (BMI 25.0-29.9 kg/m2) 33.0 33.2 0.2 0.6 0.8668

Obese (BMI>=30 kg/m2) 46.1 43.0 -3.1 -6.6 0.0009

High waist measurement (male>40 inches) 43.8 37.4 -6.4 -14.6 0.0000

Prehypertension (>=120/80 and <140/90 mmHg) 64.4 47.7 -16.7 -25.9 0.0000

Hypertension (>=140/90 mmHg) 13.1 15.1 2.0 15.0 0.1426

Metabolic syndrome**** 33.8 26.8 -7.0 -20.8 0.0000

Total cholesterol >=200 mg/dL 48.3 37.7 -10.6 -21.9 0.0000

HDL <40 mg/dL 34.4 28.2 -6.1 -17.8 0.0000

LDL >=130 mg/dL 39.6 31.6 -8.0 -20.2 0.0000

LDL >=ATP III suggested goal 33.9 29.6 -4.2 -12.5 0.0001

Triglyceride >=150 mg/dL 40.2 33.2 -7.0 -17.4 0.0000

Undiagnosed diabetes (glucose>=126 mg/dL) 5.2 4.1 -1.1 -20.8 0.1309

Prediabetes (100<=glucose<126 mg/dL) 26.5 28.8 2.4 9.0 0.1382

Clinical Measures with Numerical Values

Weight (lbs) 207.1 204.0 -3.1 -1.5 0.0000

BMI (kg/m2) 30.1 29.6 -0.5 -1.7 0.0000

Waist (inch) 39.9 39.2 -0.7 -1.7 0.0000

Exercise level (1=Low; 2=Moderate; 3=High) 1.7 1.8 0.2 9.0 0.0000

Systolic blood pressure (mmHg) 125.3 123.3 -2.0 -1.6 0.0000

Diastolic blood pressure (mmHg) 77.5 77.4 -0.1 -0.1 0.8540

Total cholesterol (mg/dL) 200.6 191.2 -9.4 -4.7 0.0000

HDL cholesterol (mg/dL) 45.1 46.4 1.3 2.8 0.0000

LDL cholesterol (mg/dL) 124.1 116.2 -7.9 -6.4 0.0000

Triglyceride (mg/dL) 163.1 146.2 -16.9 -10.4 0.0000

Fasting glucose (mg/dL) 102.3 101.7 -0.6 -0.6 0.4022

Health Status and Risk Factor Profile:

Changes Between Baseline & Follow-Up (continued)

Males

Page 6Client: ABC Corporation

Date of Comparison Report: 11/20/09

Type 2 Diabetes Coronary Heart Disease

Relatively

High

Above

AverageAverage

Below

Average

Relatively

Low

Relatively

High

Above

AverageAverage

Below

Average

Relatively

Low

Baseline 24% 20% 22% 16% 18% Baseline 24% 27% 22% 16% 11%

Follow up 21% 20% 21% 18% 20% Follow up 18% 24% 21% 20% 17%

Baseline* N = 1,284 Baseline N = 1,404

Follow-up** N = 1,276 Follow-up N = 1,404

Stroke Heart Failure

Relatively

High

Above

AverageAverage

Below

Average

Relatively

Low

Relatively

High

Above

AverageAverage

Below

Average

Relatively

Low

Baseline 32% 23% 18% 14% 13% Baseline 22% 24% 18% 18% 18%

Follow up 28% 21% 19% 17% 15% Follow up 20% 20% 19% 20% 21%

Baseline N = 1,389 Baseline N = 711

Follow-up N = 1,387 Follow-up N = 752

Disease risk is classified by an age- and gender-specific risk percentile as follows:

Relatively High >=80th percentile

Above Average >=60th and < 80th percentile

Average >=40th and <60th percentile

Below Average >=20th and <40th percentile

Relatively Low <20th percentile

* Baseline N refers to the number of people who received a KYN risk prediction at baseline for the specific disease.

** Follow-up N refers to the number of people who received a KYN risk prediction at follow-up for the specific disease.

No data for COPD and lung cancer because those models were only run for smokers.

Distribution of Population Disease Risks by Percentile

0%

5%

10%

15%

20%

25%

Relatively High

Above Average

Average Below Average

Relatively Low

0%

5%

10%

15%

20%

25%

30%

Relatively High

Above Average

Average Below Average

Relatively Low

0%

5%

10%

15%

20%

25%

30%

35%

Relatively High

Above Average

Average Below Average

Relatively Low

0%

5%

10%

15%

20%

25%

Relatively High

Above Average

Average Below Average

Relatively Low

Page 7Client: ABC Corporation

Date of Comparison Report: 11/20/09

Type 2 Diabetes Coronary Heart Disease

Follow-Up

***

Total 51.7 46.0 -11% 0.00 Total 40.3 33.8 -16% 0.00

Avoidable 42.8 37.2 -13% 0.00 Avoidable 27.1 21.3 -21% 0.00

Stroke Heart Failure

Total 22.8 20.8 -9% 0.00 Total 8.7 8.3 -5% 0.00

Avoidable 16.9 14.7 -13% 0.00 Avoidable 2.5 2.2 -9% 0.00

* "Total cases" is the predicted number of new cases in the study population over the next 5 years.

**** Change (%) is the difference in avoidable cases between follow-up and baseline evaluations divided by the baseline.

Baseline

Predicted Number of Total* and Avoidable Cases** of Disease Onset Within the Next Five Years:

Changes Between Baseline and Follow-Up Evaluations

Baseline Change****P

Value***** Baseline Follow-Up Change P Value

** "Avoidable cases" is the number of new cases that can be avoided in the next 5 years, if all modifiable risk factors are brought

within the normal range.

*** Follow-up is the re-prediction for the same 5-year window as baseline. It recalculates the risk using age and non-modifiable

risk factors from the baseline and modifiable risk factors from the follow-up.

***** P value is based on a paired t-test or chi-square analysis. P<0.05 indicates that the difference between the baseline and

follow-up evaluations is statistically significant and is shown in red.

Follow-Up ChangeP Value P ValueBaseline Follow-Up Change

0.0

10.0

20.0

30.0

40.0

50.0

60.0

Total Avoidable

Nu

mb

er

of ca

se

s

Baseline Follow-Up

0.0

5.0

10.0

15.0

20.0

25.0

Total Avoidable

Nu

mb

er

of ca

se

s

Baseline Follow-Up

0.01.02.03.04.05.06.07.08.09.0

Total Avoidable

Nu

mb

er

of ca

se

s

Baseline Follow-Up

0.0

10.0

20.0

30.0

40.0

50.0

Total Avoidable

Num

be

r o

f ca

se

sBaseline Follow-Up

Page 8Client: ABC Corporation

Date of Comparison Report: 11/20/09

COPD

Total 24.28 25.11 3% 0.00

Avoidable 9.85 10.12 3% 0.00

Lung Cancer

Total 1.44 1.71 19% 0.15

Avoidable 0.83 0.98 18% 0.18

Predicted Number of Total and Avoidable Cases of Disease Onset Within the Next Five Years:

Changes Between Baseline and Follow-Up Evaluations

Baseline Follow-Up Change P Value

Baseline Follow-Up Change P Value

(continued)

0.00

5.00

10.00

15.00

20.00

25.00

30.00

Total Avoidable

Nu

mb

er

of ca

se

s

Baseline Follow-Up

0.000.200.400.600.801.001.201.401.601.80

Total Avoidable

Num

ber

of ca

se

s

Baseline Follow-Up

Page 9Client: ABC Corporation

Date of Comparison Report: 11/20/09

Baseline Follow-up

Weight 42.2 40.5 -4%

Blood Pressure 9.3 6.9 -26%

Exercise 11.6 9.1 -21%

Smoking 22.2 18.8 -15%

Cholesterol 9.3 6.1 -35%

Glucose 4.1 4.2 3%

Aspirin 1.2 0.9 -22%

Total 99.8 86.6 -13%

** Diseases include type 2 diabetes, coronary heart disease, stroke, heart failure, COPD, and lung cancer.

Contribution of Risk Factors to Avoidable Cases* of Each Disease**:

Changes Between Baseline & Follow-Up

* "Avoidable cases" is the number of new cases that can be avoided in the next 5 years, if all modifiable risk factors are brought

within the normal range.

Risk Sources ChangeAvoidable Cases

0.0

5.0

10.0

15.0

20.0

25.0

30.0

35.0

40.0

45.0

Weight Blood Pressure Exercise Smoking Cholesterol Glucose Aspirin

Nu

mb

er

of ca

se

s

Baseline

Follow-up

Page 10Client: ABC Corporation

Date of Comparison Report: 11/20/09

Total Population N = 1520

Type 2 Diabetes Coronary Heart Disease

Follow-Up***

Total 56.0 49.8 -11% Total 43.6 36.6 -16%

Avoidable 46.3 40.3 -13% Avoidable 29.3 23.1 -21%

Stroke Heart Failure

Total 24.7 22.6 -9% Total 9.4 9.0 -5%

Avoidable 18.2 15.9 -13% Avoidable 2.7 2.4 -9%

* Total population is the population that the study population represents.

** Total cases refer to predicted new cases in the next 5 years.

*** Avoidable cases are the cases that can be avoided in the next 5 years, if all modifiable risk factors are brought within the normal range.

**** Follow-up is the re-prediction for the same 5-year window as baseline. It recalculates the risk using age and non-modifiable

risk factors from the baseline and modifiable risk factors from the follow-up.

***** Change is the difference in cases between follow-up and the baseline as a percentage of the baseline.

Baseline Follow-Up ChangeBaseline Follow-Up Change

Extrapolation to Total Population*

Predicted Number of Total** and Avoidable*** Cases of Disease Onset Within the Next Five Years:

Changes Between Baseline and Follow-Up

Baseline Change***** Baseline Follow-Up Change

0.0

20.0

40.0

60.0

Baseline Follow-Up***

Nu

mb

er

of ca

se

s

Total Avoidable

0.0

5.0

10.0

15.0

20.0

25.0

Baseline Follow-Up

Nu

mb

er

of ca

se

s

Total Avoidable

0.0

2.0

4.0

6.0

8.0

10.0

Baseline Follow-Up

Num

be

r o

f ca

se

s

Total Avoidable

0.0

10.0

20.0

30.0

40.0

50.0

Baseline Follow-Up

Nu

mb

er

of ca

se

s

Total Avoidable

Page 11Client: ABC Corporation

Date of Comparison Report: 11/20/09

Total Population: N = 1520

COPD

Total 26.3 27.2 3%

Avoidable 10.7 11.0 3%

Lung Cancer

Total 1.56 1.85 19%

Avoidable 0.90 1.06 18%

Baseline Follow-Up Change

Extrapolation to Total Population

Predicted Total & Avoidable Cases of Disease Onset within Next Five Years:

Changes Between Baseline and Follow-Up

(continued)

Baseline Follow-Up Change

0.0

5.0

10.0

15.0

20.0

25.0

30.0

Baseline Follow-Up

Nu

mb

er

of ca

se

s

Total Avoidable

0.00

0.50

1.00

1.50

2.00

Baseline Follow-Up

Nu

mb

er

of ca

se

s

Total Avoidable

Page 12Client: ABC Corporation

Date of Comparison Report: 11/20/2009

Total Population: N = 1520

Baseline Follow-Up

Weight 45.7 43.8 -4%

Blood Pressure 10.1 7.5 -26%

Exercise 12.5 9.9 -21%

Smoking 24.0 20.4 -15%

Cholesterol 10.1 6.6 -35%

Glucose 4.4 4.6 3%

Aspirin 1.3 1.0 -22%

Total 108.1 93.7 -13%

** Diseases include type 2 diabetes, coronary heart disease, stroke, heart failure, COPD, and lung cancer.

Extrapolation to Total Population

Changes Between Baseline & Follow-Up

Avoidable Cases

* "Avoidable cases" is the number of new cases that can be avoided in the next 5 years, if all modifiable risk factors are brought

within the normal range.

Contribution of Risk Factors to Avoidable Cases* of Each Disease**:

Risk Sources Change

0.0

5.0

10.0

15.0

20.0

25.0

30.0

35.0

40.0

45.0

50.0

Weight Blood Pressure Exercise Smoking Cholesterol Glucose Aspirin

Nu

mb

er

of ca

se

s

Baseline

Follow-Up

Page 13Client: ABC Corporation

Date of Comparison Report: 11/20/09

Study Population: N = 1404

Diseases Baseline Follow-Up Difference***

Type 2 Diabetes $1,285,133 $1,143,445 -$141,688

Coronary Heart Disease $984,831 $825,988 -$158,844

Stroke $643,701 $587,236 -$56,465

Heart Failure $142,811 $136,245 -$6,566

COPD $213,901 $220,943 $7,042

Lung Cancer $124,236 $150,858 $26,622

All Diseases $3,394,612 $3,064,714 -$329,899

Total Population: N = 1520

Diseases Baseline Follow-Up Difference

Type 2 Diabetes $1,392,020 $1,237,904 -$154,117

Coronary Heart Disease $1,065,475 $894,413 -$171,063

Stroke $697,343 $638,055 -$59,288

Heart Failure $154,301 $147,735 -$6,566

COPD $231,506 $239,428 $7,922

Lung Cancer $141,984 $159,732 $17,748

All Diseases $3,682,629 $3,317,266 -$365,363

* Predicted costs = probability of disease onset (KYN) x 2.5 years x annual cost of disease (noted below).

** Study population is the population who participated in Know Your Number.

*** Difference = follow-up estimated costs minus baseline estimated costs.

**** The study population is considered to be a representative subset of the larger total population.

Estimated Five-year Cost* of Future Chronic Disease Onset:

Changes Between Baseline and Follow-Up

Study Population**

The annual costs (per patient) were as follows: type 2 diabetes = $9,943; coronary heart disease = $9,775; stroke = $11,293;

heart failure = $6,566; COPD = $3,521; and lung cancer = $35,496.

Estimates include direct and indirect medical costs associated with occurrence of each disease and were calculated using

current national average annual costs, as reported by the American Diabetes Association, the American Heart Association, the

American Stroke Association, the American Lung Association, and National Cancer Institute.

Extrapolation to Total Population****